Hepatocellular carcinoma (HCC) is a primary malignancy of the liver that commonly arises from underlying liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx), an angiogenesis inhibitor, was the only drug approved for advanced-stage patients until the recent approvals of Stivarga (Bayer HealthCare), Opdivo (Bristol-Myers Squibb / Ono Pharmaceuticals), Keytruda (Merck & Co.), Lenvima (Eisai / Merck & Co.), Cabometyx (Exelixis), and Cyramza (Eli Lilly). The late-phase development pipeline is predominantly focused on the advanced-stage HCC segment and encompasses a diverse range of mechanisms of action. Because the HCC market remains largely untapped, the developer of an efficacious therapy could reap high commercial rewards.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 22 country-specific interviews with thought leaders (medical oncologists and hepatologists).
Key companies: Bayer HealthCare/Amgen/Onyx , Bristol-Myers Squibb/Ono Pharmaceutical, Merck & Co., Eisai, Exelixis/Ipsen.
Key drugs: Nexavar, Stivarga, Opdivo, Lenvima, Keytruda, Cabometyx, Cyramza.
Population segments in market forecast: Early-stage, first-line intermediate-stage, second-line intermediate-stage, first-line advanced-stage, and second-line advanced-stage hepatocellular carcinoma.
Emerging therapies: Phase III: approximately 7 drugs; Phase II: approximately 15 drugs; coverage of select Phase I and preclinical products.